TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25910473
Drug: Naloxone Intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone Intranasal Delivery System (NXN)
Study: 23834117
Drug: ETN 50
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN 50 mg twice weekly
Study: 23834117
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NB‐UVB phototherapy and ETN
Study: 21538218
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (pulsed infrared laser) and exercise therapy for ten sessions over 2 weeks
Study: 21538218
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser and exercise therapy for ten sessions over 2 weeks
Study: 10750290
Drug: Bladder filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder filled with 300 ml
Study: 10750290
Drug: Bladder filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder filled with 200 ml
Study: 8777274
Drug: 100 ng
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ng LPS/ml
Study: 8777274
Drug: Medium doses
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium doses of LPS (100 ng/ml)
Study: 8777274
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of LPS (1 ng/ml)
Study: 2050425
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefodizime
Study: 2050425
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefodizime
Study: 6342956
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sodium meclofenamate 3-times daily
Study: 22829919
Drug: Controls (sulfadoxine-pyrimethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controls (sulfadoxine-pyrimethamine twice)
Study: 22829919
Drug: Monthly sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulfadoxine-pyrimethamine (SP) among HIV-negative participants
Study: 22829919
Drug: Monthly sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulfadoxine-pyrimethamine and two doses of azithromycin (AZI-SP) among HIV-negative participants
Study: 9329511
Drug: Naproxen (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (750 mg daily for 8 weeks)
Study: 9329511
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg, each given orally four times daily for 1 week) followed by naproxen (750 mg daily for 8 weeks)
Study: 2663937
Drug: Topical ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketanserin (2% ointment)
Study: 194691
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (cyclophosphamide, methotrexate, CCNU)
Study: 194691
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy (cyclophosphamide, methotrexate, CCNU)
Study: 31743533
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 0.25 mg/kg preoperatively, followed by 0.25 mg/kg/hr intraoperatively, and 0.1 mg/kg/hr from 1 hr before the end of surgery until the end of recovery room stay
Study: 26076867
Drug: avibactam 500
Normalized name: avibactam 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: avibactam 500 mg
Study: 26076867
Drug: ceftazidime 2000
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftazidime 2000 mg plus avibactam 500 mg
Study: 23260506
Drug: Physician management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician management plus cognitive behavioral therapy
Study: 22980100
Drug: Community-based psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based psychosocial intervention consisting of 12 sessions (30 minutes of relaxation exercises and 75 minutes of structured support groups) delivered twice per week over six weeks.
Study: 15361773
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion (10, 20 and 40 ng/kg per min for 30 min)
Study: 9863121
Drug: Chinese herbs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbs combined with chemotherapy
Study: 3528087
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + MISO (400 mg/M2 2‐4 hours prior to RT daily, maximum 12 gm/M2)
Study: 24045440
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by local therapy (radiation and/or surgery) and adjuvant chemotherapy
Study: 24045440
Drug: Chemotherapy/surgery alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy/surgery alone
Study: 18564626
Drug: Etoricoxib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (45 mg on day 2, 90 mg on day 3)
Study: 16033730
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (premeal)
Study: 16033730
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (postmeal)
Study: 16033730
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (premeal)
Study: 12472702
Drug: Methohexital (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (10 mg.ml‐1) combined with remifentanil (6.67 micro g.ml‐1)
Study: 10051728
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FP) 200 microg once daily for 4 weeks
Study: 10051728
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FP)
Study: 2140546
Drug: Clarithromycin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (two 250 mg tablets twice daily)
Study: 2140546
Drug: Amoxycillin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (two 500 mg capsules twice daily)
Study: 28892233
Drug: HA microneedle
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA microneedle patch
Study: 23689006
Drug: Revascularization treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revascularization treatment with calcium hydroxide
Study: 11367972
Drug: Listerine Antiseptic
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listerine Antiseptic (L)
Study: 3595068
Drug: Fasting (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting (10 mg nifedipine)
Study: 3595068
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (10 mg nifedipine)
Study: 3595068
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (10 mg nifedipine)
Study: 31886707
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide (500 mg/day)
Study: 30176845
Drug: Systematic self-monitoring
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systematic self-monitoring (5 times per day) and weekly personalized feedback on positive affect and activities ("Do"-module)
Study: 30176845
Drug: Systematic self-monitoring
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systematic self-monitoring (5 times per day) and weekly personalized feedback on negative affect and thinking patterns ("Think"-module)
Study: 24407896
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia with TCI (Group A)
Study: 21312290
Drug: Amantadine (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (100-150 mg/day depending on weight)
Study: 21312290
Drug: Methylphenidate (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (20-30 mg/day)
Study: 18186057
Drug: Biological/genetic explanation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological/genetic explanation of anorexia nervosa
Study: 16817177
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg abciximab bolus administered early in the emergency department
Study: 16817177
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg abciximab bolus administered late in the catheterization laboratory
Study: 12538427
Drug: L‐NMMA (NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (NO synthase inhibitor)
Study: 12538427
Drug: Vascular cell
Normalized name: Autologous stromal vascular cell fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular cell adhesion molecule-1
Study: 1658648
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange twice weekly for three weeks
Study: 30779333
Drug: SMART-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART-based treatment (online lessons, self-monitoring, feedback, monthly weigh-ins)
Study: 30779333
Drug: GROUP-based treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GROUP-based treatment (weekly meetings for 6 months, biweekly for 6 months, monthly for 6 months, self-monitoring via paper diaries with written feedback)
Study: 30779333
Drug: CONTROL (self-monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONTROL (self-monitoring via paper diaries with written feedback and monthly weigh-ins)
Study: 28134840
Drug: A2 milk
Normalized name: Pure Bliss A2 Milk Infant Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: A2 milk (500 mL)
Study: 28134840
Drug: Regular milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular milk (500 mL)
Study: 28134840
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) (500 mL)
Study: 28134840
Drug: Milk treatments
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk treatments (A2 and regular)
Study: 23283923
Drug: Xylitol lozenges
Normalized name: xylitol Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol lozenges (5 lozenges of 1.0 gram daily for 33 months)
Study: 23283923
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges (5 lozenges daily for 33 months)
Study: 20868639
Drug: Extended dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended dosing (every second day)
Study: 20868639
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing (usual medication)
Study: 15796091
Drug: PMBL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMBL treatment (sublingual tablet taken for ten consecutive days over three consecutive months)
Study: 15796091
Drug: PMBL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMBL treatment
Study: 15796091
Drug: Device for
Normalized name: vibrating transient device for constipation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device for PMBL treatment
Study: 11405516
Drug: Self-treatment guidelines
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment guidelines (group S)
Study: 8375243
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline (0.25 mg)
Study: 29023624
Drug: Pedicled buccal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pedicled buccal fat pad with Emdogain (group I; n = 5)
Study: 29023624
Drug: Pedicled buccal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pedicled buccal fat pad alone (group II; n = 5)
Study: 26141306
Drug: Heparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5,000 U/mL locks
Study: 16273330
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (polyethylene glycol; Group 1)
Study: 16273330
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation (Group 2)
Study: 10632003
Drug: Balanced saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced saline solution (BSS) (group III)
Study: 10632003
Drug: No adjunct
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunct (group IV)
Study: 9110100
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day for six weeks
Study: 8237626
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide by intravenous bolus
Study: 8237626
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide orally
Study: 8237626
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide (both intravenous and oral)
Study: 29614960
Drug: Chair based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chair based exercise (CCBE) delivered once a week in day centres and community groups, and twice a week in care homes.
Study: 16034448
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg QD (Treatment phase-1)
Study: 16034448
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg QD (Treatment phase-2)
Study: 12047009
Drug: Combination antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antipsychotics (specifically augmentation of clozapine)
Study: 12047009
Drug: Clozapine (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (as a monotherapy)
Study: 2193265
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic therapy (cephalexin 500 mg every 6 hours)
Study: 2193265
Drug: Intravenous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic therapy (cephalothin 1 g every 6 hours)
Study: 2193265
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (oral and IV)
Study: 361000
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 mg every 8 hours when rectal temperature >= 38.5°C)
Study: 361000
Drug: Phenobarbitone (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (3.5 +/- 1 mg/kg per day)
Study: 23364373
Drug: Ketamine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine + Atropine (0.01 mg/kg)
Study: 22193788
Drug: Weekly feedback
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly feedback to clinicians
Study: 26788345
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil (GEn) 1200 mg
Study: 15234478
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection (acute pain)
Study: 15234478
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection (fear of pain)
Study: 7566020
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg each evening)
Study: 2190884
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (HD-CTX) with rhGM-CSF (5.5 micrograms/kg/day by continuous iv infusion for 14 days)
Study: 2190884
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (HD-CTX) without rhGM-CSF
Study: 2190884
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (HD-CTX) with rhGM-CSF
Study: 474381
Drug: GIK (30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK (30% glucose solution with 50 units of regular insulin and 80 mM KCl per liter, 50 mol. bolus followed by 1 ml./Kg./hr.)
Study: 474381
Drug: NSS (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSS (normal saline, 50 mol. bolus followed by 1 ml./Kg./hr.)
Study: 31789800
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation (supervised exercise therapy) in addition to standard care (10 days of prednisolone, general information, and counseling)
Study: 25487899
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gluconate surgical preparation
Study: 21603893
Drug: Ketamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (100 ng/ml blood plasma level)
Study: 17394048
Drug: Oral polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polyethylene glycol lavage solution and enemas (group A)
Study: 17394048
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation (group B)
Study: 15338804
Drug: Daily symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily symptoms
Study: 15338804
Drug: Asthma symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthma symptoms and beta-agonist use
Study: 9555777
Drug: Oral d-sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral d-sotalol
Study: 27117531
Drug: Pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 mg/kg Q3W
Study: 27117531
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg Q3W
Study: 27117531
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg Q2W
Study: 23883162
Drug: Anma massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anma massage therapy (40-min session once weekly for 2 months, total of 8 sessions)
Study: 23883162
Drug: Anma massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anma massage therapy
Study: 16458680
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (12 argon spots)
Study: 11182624
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy initiated within 24 hours after the onset of symptoms of an acute MI
Study: 11182624
Drug: Aspirin in
Normalized name: Non-Aspirin Infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin in patients with prior occlusive cardiovascular disease
Study: 11182624
Drug: Aspirin in
Normalized name: Non-Aspirin Infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin in primary prevention trials
Study: 24986183
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) among older adults
Study: 18786230
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg teriparatide (PTH 1‐34) daily subcutaneous injections
Study: 2143597
Drug: Ramipril alone
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril alone (2.5-5 mg/day)
Study: 2143597
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg in combination with furosemide 20 mg
Study: 25143337
Drug: Cyclosporine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (3 mg/kg per day for 8 weeks)
Study: 25143337
Drug: Acitretin (0.3-0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (0.3-0.5 mg/kg per day for 8 weeks)
Study: 15495698
Drug: Bed rest
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bed rest as a therapy
Study: 9231668
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who failed treatment
Study: 29561278
Drug: Lung-protective ventilation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung-protective ventilation (LPV group) [tidal volume 5 ml/kg ideal body weight + PEEP between 5 and 8 cmH2O]
Study: 29561278
Drug: Nonprotective ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonprotective ventilation (control group) [tidal volume 10 ml/kg ideal body weight without PEEP]
Study: 27108261
Drug: Posterior decompression,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior decompression, bone cement augmentation and internal fixation (n=14)
Study: 17525884
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (E) - home-based walking program, aerobic walking at target heart rate for 20 minutes or more daily, 2 or more days a week
Study: 12100806
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (six weekly instructional sessions on bladder training and individualized voiding schedules)
Study: 12100806
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (after 6 weeks for all women)
Study: 10344481
Drug: Moisturizer applied
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizer applied on one arm/hand 3x daily for 9 days